Rigel Pharmaceuticals Misses Q1 Revenue Estimates, Reaffirms Profitable FY Outlook
Summary
Rigel Pharmaceuticals reported Q1 revenue of $58.80 million, falling short of analyst estimates of $62.39 million. Net income for the quarter also declined to $8.7 million from $11.4 million a year prior. Despite this, the company reaffirmed its 2026 revenue outlook and anticipates achieving positive net income for the full fiscal year, with net product sales rising 26% year-over-year. This mixed earnings report follows the recent termination of a collaboration agreement with Eli Lilly for the RIPK1 inhibitor ocadusertib on April 21st, adding to recent operational challenges. The Q1 revenue miss and lower net income could create near-term pressure on the stock, as current performance often outweighs future guidance. Traders will closely monitor if Rigel can meet its reaffirmed full-year guidance and demonstrate continued progress in its clinical pipeline.
At the time of this announcement, RIGL was trading at $25.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $519.1M. The 52-week trading range was $16.88 to $52.24. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.